Spike Protein News and Research

RSS

Lipids, COVID-19, and host immunity

A new study from a team of researchers at the University of Pennsylvania examines the role played by lipids in this disease.

10 Oct 2021

Powerful neutralizing antibody against SARS-CoV-2 variants of concern

A new paper discusses a new antibody with potent neutralizing activity against the ancestral SARS-CoV-2 strain, as well as newer variants of SARS-CoV-2.

10 Oct 2021

Study supports efficacy and safety of lung-selective nanotherapy against SARS-CoV-2 infection

A new preprint shows the potential role of a host protease cathepsin L inhibitor, which mediates viral entry into the host cell by its effect on the viral spike protein.

8 Oct 2021

Oral and intranasal COVID-19 vaccines show promising results in hamster model

A new preprint discusses the protective effect of an oral adenovirus-vectored vaccine based on the SARS-CoV-2 spike against viral transmission and disease in hamsters.

8 Oct 2021

mRNA vaccination associated with decreased risk of COVID-19 infection and hospitalization in U.S. veterans

Researchers from the U.S. Veterans Affairs have examined the U.S. effort to vaccinate its Veteran population to investigate further.

8 Oct 2021

Assay to assess and quantify presence of RBD-directed antibodies against SARS-CoV-2 following vaccination

Researchers from Roche Diagnostics have been testing a new assay known as the Elecsys assay.

8 Oct 2021

Adapting biological research and development to COVID-19

In this interview, News-Medical talks to Dr Yuning Chen, about the work he does with Sino Biological and how they have adapted their research & development to the COVID-19 pandemic.

From Sino Biological Inc. 8 Oct 2021

Scientists study immune response to COVID-19 in patients with different levels of disease severity

Researchers from Skoltech, U.S. companies VirIntel and Argentys Informatics, and two Russian Academy of Sciences institutes have studied the immune response to COVID-19 in patients with different levels of disease severity.

8 Oct 2021

Israeli Pfizer COVID vaccine/myocarditis study, 136 cases out of 5 million

A new study, published in the New England Journal of Medicine, aimed to present clinical, epidemiological, and follow-up findings of myocarditis cases diagnosed in temporal proximity to COVID-19 vaccination and explore the possibility of a causal relationship between the two.

7 Oct 2021

non-RBD mutation in SARS-CoV-2 variants enhances resistance to neutralizing antibodies

Researchers from Ohio State University have been investigating mutations in the rest of the spike protein, particularly the Q677H mutation.

7 Oct 2021

SARS-CoV-2 evolution promoted by long-term infection in patient with B cell depletion

A new study published on the medRxiv* preprint server focused on a patient with a persistent symptomatic viral infection for over a year. Researchers amplified sub-genomic transcripts for the E gene (sgE) using nasopharyngeal samples of the patient infected with SARS-CoV-2 over the course of 335 days.

6 Oct 2021

Study shows new antibody resistant variants can emerge in patients treated with monoclonal antibodies

A new study, published on the medRxiv* preprint server, suggested that selective pressures induced by the administration of monoclonal antibodies (Bamlanivimab) may require increased genomic surveillance to identify and control the spread of therapy-induced variants.

6 Oct 2021

Graphene biosensor in a portable and wireless device for rapid SARS-CoV-2 detection

A new study posted to the medRxiv* server and led by Dr. Mattia D'Agostino, Dr. Eleonora Pavoni and Dr. Alice Romagnoli from the Polytechnic University of Marche in Ancona (Italy), a gFET biosensor that uses angiotensin-converting enzyme 2 (ACE2) as a bioreceptor has been put forth as a viable solution.

6 Oct 2021

Durability of immunity to SARS-CoV-2 reinfection

The current study used data on the durability of immunity among evolutionarily close coronavirus relatives of SARS-CoV-2 to estimate times to reinfection.

6 Oct 2021

Study shows strong protective effect of IgG3 antibodies in SARS-CoV-2 infection

Researchers published a study on the expression and functional analyses of a neutralizing mAb with identical variable domains but different constant HCs, representing IgG1-4.

6 Oct 2021

Study shows lower SARS-CoV-2 infection rates in smokers

Coronavirus disease 2019 (COVID-19) primarily infects the lungs, later spreading through the bloodstream. The worst prognoses are mostly seen in ‘at-risk’ groups, such as the immunocompromised, elderly, or those suffering from respiratory conditions.

6 Oct 2021

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

Researchers in the United States have shown that a compound currently used to treat cystinosis exhibits broad antiviral activity against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

Plasmid DNA vaccines induce effective antibody responses against SARS-CoV-2 in mice

Researchers in the United States and China have developed plasmid DNA immunogens that induce effective antibody responses in mice against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Your saliva may be able to tell you if you’ve developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, suggests a new medRxiv* preprint study. In immunocompromised groups, salivary Immunoglobulin G (IgG) antibody levels were associated with IgG titers in blood serum 3 to 4 weeks after mRNA vaccination.

5 Oct 2021

SARS-CoV-2 mRNA vaccines elicit higher levels of antibodies compared to natural infection

Researchers from the US recently characterized the scale and specificity of SARS-CoV-2 spike-reactive antibodies from 23 participants who received SARS-CoV-2 mRNA vaccines and 10 acutely infected health care workers. They found that primary mRNA vaccination and infection elicited S1- and S2-reactive antibodies, while secondary mRNA vaccination elicited mostly S1 antibodies.

4 Oct 2021

Spike Protein News and Research

Lipids, COVID-19, and host immunity

Powerful neutralizing antibody against SARS-CoV-2 variants of concern

Study supports efficacy and safety of lung-selective nanotherapy against SARS-CoV-2 infection

Oral and intranasal COVID-19 vaccines show promising results in hamster model

mRNA vaccination associated with decreased risk of COVID-19 infection and hospitalization in U.S. veterans

Assay to assess and quantify presence of RBD-directed antibodies against SARS-CoV-2 following vaccination

Adapting biological research and development to COVID-19

Scientists study immune response to COVID-19 in patients with different levels of disease severity

Israeli Pfizer COVID vaccine/myocarditis study, 136 cases out of 5 million

non-RBD mutation in SARS-CoV-2 variants enhances resistance to neutralizing antibodies

SARS-CoV-2 evolution promoted by long-term infection in patient with B cell depletion

Study shows new antibody resistant variants can emerge in patients treated with monoclonal antibodies

Graphene biosensor in a portable and wireless device for rapid SARS-CoV-2 detection

Durability of immunity to SARS-CoV-2 reinfection

Study shows strong protective effect of IgG3 antibodies in SARS-CoV-2 infection

Study shows lower SARS-CoV-2 infection rates in smokers

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

Plasmid DNA vaccines induce effective antibody responses against SARS-CoV-2 in mice

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

SARS-CoV-2 mRNA vaccines elicit higher levels of antibodies compared to natural infection

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News